Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study published online May 17 in JAMA Network Open.
Nadine Khoury, from Universitat Rovira i Virgili in Italy, and colleagues examined the association between UPF consumption and cardiometabolic risk in children. The analysis included 1,426 participants (aged 3 to 6 years) in the Childhood Obesity Risk Assessment Longitudinal Study.
The researchers found that compared with participants in the lowest tertile of energy-adjusted UPF consumption, those in the highest tertile showed higher z scores of body mass index (BMI; β coefficient, 0.20), waist circumference (β coefficient, 0.20), fat mass index (β coefficient, 0.17), and fasting plasma glucose (β coefficient, 0.22), as well as lower z scores for high-density lipoprotein (HDL) cholesterol (β coefficient, −0.19). Each one standard-deviation increment in energy-adjusted UPF consumption was associated with higher z scores for BMI (β coefficient, 0.11), waist circumference (β coefficient, 0.09), fat mass index (β coefficient, 0.11), and fasting plasma glucose (β coefficient, 0.10), as well as lower HDL cholesterol (β coefficient, −0.07). When substituting 100 g of UPFs with 100 g of unprocessed or minimally processed foods, there was an association with lower z scores of BMI (β coefficient, −0.03), fat mass index (β coefficient, −0.03), and fasting plasma glucose (β coefficient, −0.04).
"These findings highlight the need for public health initiatives to promote the replacement of UPFs with unprocessed or minimally processed foods," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.